JeffreyABubisDOFACOI, FACP

PubMed

• 225 citations
  Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
  Joachim von Pawel, Robert M. Jotte, David R. Spigel, Mary O'Brien, Mark A. Socinski
  Journal of Clinical Oncology. 2014-11-10
• 17 citations
  TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
  Denise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky
  Breast Cancer Research and Treatment. 2017-05-15
• 23 citations
  Docetaxel in the Treatment of Esophageal Cancer
  James R. Rigas, Konstantin H. Dragnev, Jeffrey A. Bubis
  Seminars in Oncology. 2005-04-01

Journal Articles

• Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer  
  Pawel J, Jotte R, Spigel DR, O’Brien MER, Socinski MA, Mezger J, Steins M, Bosuee L, Bubis J, Nackaerts K, Trigo JM, Clinigan P, Schutte, Lorigan P, Reck M, Domine M, ..., JCO, 1/1/2014
• Trimodality therapy for stage II-III carcinoma of the esophagus: A dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy  
  Wood MD, Zaki BI, Gordon SR, Sutton JE, Lisovsky M, Gui J, Bubis JA, Dragnev KH, Rigas JR, Journal of Thoracic Oncology, 1/1/2013
• First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel  
  Oudard S, Sengelov L, Mainwaring PN, Thiery-Vuillemin A, Theodore,C, Kulukov E, Yachnin J, Kocak I, Kataja VV, Luukkaa M, Nosov A, Hjelm-Eriksson M, Bubis J, et al, J Clin Oncol, 1/1/2012
• Trimodality therapy for stage II-III carcinoma of the esophagus: A dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy  
  Wood MD, Zaki BI, Gordon SR, Sutton JE, Lisovsky M, Gui J, Dragnev KH, Bubis JA, Rigas JR, J Clin Oncol, 1/1/2012
• Prevalence of paroxysmal nocturnal hemaglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other bone marrow failure syndr...  
  Galli N, Ravandi F, Palermo G, Bubis J, Illingworh A, Castro-Malaspina H, Raza A, J Clin Oncol; ASCO Annual Meeting Proceedings, 1/1/2009
• Pilot study of low dose melphalan and bortezomib for treatment of acute myelogenous leukemia and high-risk myelodysplastic syndromes  
  Bubis JA, Ely P, Meehan KR, Stearns D, Schaal AD, Kimtis EA, Lowrey C, Bengtson EM, Hill J, Gautier M, American Society of Hematology Annual Meeting, 1/1/2005
• Synergistic effects of bortezomib with low dose melphalan against human AML cells  
  Gautier M, Bubis JA, Wu J, Meehan JR, American Society of Hematology Annual Meeting, 1/1/2005
• Subcutaneous administration of alemtuzumab: a single instutiton experience  
  Bubis JA, Schaal AD, Kimtis EA, Gautier M, American Society of Hematology Annual Meeting, 1/1/2005
• Docetaxel in the Treatment of Esophageal Cancer  
  Rigas JR, Dragnev KH, Bubis JA, Seminars in Oncology, 1/1/2005
• Temporal manipulation of ejaculate components by newly fertilized Drosophila melanogaster females  
  Bubis JA, DeGreen HP, Unsell JL., Tompkins L, Animal Behaviour, 1/1/1998
• Join now to see all

Books/Book Chapters

• Multidisciplinary Treatment and Management of Cancer in the Elderly 
  Chapter: Chemotherapy in the Older Cancer Patient 
  Bubis JA, Gautier M, Cohen HJEditors: Muss HB, Johnson KA, Hunter CP.Marcel Dekker, Inc.2006

Abstracts/Posters

• Features of patients (pts) with metastatic breast cancer (mBC) and a circulating tumor cell count (CTCc) of 0
  Bubis JA, Marsland TA, Justice KM, Edwards D, San Antonio Breast Cancer Symposium, 1/1/2007
• Aneusomy of chromosome (chrom) 17: an alternative mechanism of low level HER-2/neu gene amplification that correlates with immunohistochemical (IHC) 2+ protein expression
  Kaufman PA, Schwartz GN, Bubis JA, Cates J, Wells WA, Moore CP, Connelly EM, Muss HB, Weaver DL, San Antonio Breast Cancer Symposium, 1/1/2004
• Docetaxel and carboplatin followed by a dose-ranging study of oral capecitabine, weekly docetaxel, and concomitant external beam radiotherapy for the treatment of pati...
  Bubis JA, Rigas JR, Dragnev KH, Sutton JE, Gordon SR, Zaki B, Cole BF, Williams I, American Society of Clinical Oncology Annual Meeting, 1/1/2004
• Assessment of Financial Costs and Time Commitments of the Primary Caregivers of Autologous Hematopoietic Stem Cell Transplant Patients
  Bubis JA, Maginley SR, Fitzmaurice T, Meehan KR, American Society of Hematology Annual Meeting, San Diego, CA, 1/1/2003
• HER-2/neu Overexpression: Immunohistochemistry (IHC) or Fluorescence In-Situ Hybridization (FISH)?
  Bubis JA, Weaver D, Wells WA, Cole BF, Cates J, Schwartz G, Muss HB, Kaufman PA, San Antonio Breast Cancer Symposium, 1/1/2003
• Dartmouth-Hitchcock Medical Center. Is the Peripheral Blood CD34+ Cell Number the Best Indicator to Initiate Leukapheresis?
  Webber S, Leach M, Fitzmaurice T, AuBuchon J, Ely P, Meehan KR, Bubis J, and the Cellular Processing Laboratory and the Bone Marrow Transplant Program, International Society for Cellular Therapy Annual Meeting, Phoenix, AZ, 1/1/2003
• Join now to see all

Lectures

• Genomic Oncology 
  1/1/2017
• Cancer Treatment in the Elderly 
  1/1/2016
• New Options in Metastatic Colorectal Cancer 
  1/1/2015
• Contemporary Treatment Options for Metastatic Non-Small Cell Lung Cancer 
  1/1/2014
• Melanoma – A Medical Oncology Perspective 
  1/1/2013
• Adjuvant Treatment in Breast Cancer 
  1/1/2012
• Thrombophilias: A Guide to the Testing & Management of Hypercoagulable States 
  1/1/2011
• Anemia 
  1/1/2010
• The Hypercoagulable State 
  1/1/2008
• Common Hematology Issues In Primary Care 
  1/1/2007
• Breast Cancer Update 
  Orange Park, FL - 1/1/2006
• An Update On Breast Cancer For The Primary Care Physician 
  Jacksonville, FL - 1/1/2006
• The Case for Neoadjuvant Therapy In Esophageal Cancer 
  Lebanon, NH - 1/1/2004
• HER-2/neu Overexpression: Is Immunohistochemistry (IHC) or Fluorescence In-Situ Hybridization (FISH) The Better Test? 
  Orlando, FL - 1/1/2004
• HER-2/neu Overexpression: Immunohistochemistry (IHC) or Fluorescence In-Situ Hybridization (FISH)? 
  Stowe, VT - 1/1/2004
• AML In The Elderly: A Novel Approach 
  Lebanon, NH - 1/1/2003
• Interleukin-2 and Rituxan in the Treatment of Non-Hodgkin’s Lymphoma 
  Boston, MA - 1/1/2003
• An Update on Chronic Lymphocytic Leukemia 
  Lebanon, NH - 1/1/2003
• Join now to see all